NCT00049569 - Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

March 31, 2006

Conditions

L1 Childhood Acute Lymphoblastic LeukemiaL2 Childhood Acute Lymphoblastic LeukemiaNon-T, Non-B Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaT-cell Childhood Acute Lymphoblastic Leukemia

Interventions

DRUG

cytarabine

Given IT

DRUG

methotrexate

Given IT

DRUG

vincristine sulfate

Given IV

DRUG

prednisone

Given PO

DRUG

pegaspargase

Given IM

DRUG

doxorubicin hydrochloride

Given IV

DRUG

imatinib mesylate

Given PO

DRUG

cyclophosphamide

Given IV

DRUG

etoposide

Given IV

BIOLOGICAL

filgrastim

Given SC

DRUG

leucovorin calcium

Given IV

DRUG

asparaginase

Given IM

DRUG

therapeutic hydrocortisone

Given IT

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH